(VIANEWS) – Orrstown Financial Services (ORRF), Neurocrine Biosciences (NBIX), Churchill Downs (CHDN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Orrstown Financial Services (ORRF)
92.7% sales growth and 12.57% return on equity
Orrstown Financial Services, Inc. operates as the holding company for Orrstown Bank that provides commercial banking and trust services in the United States. The company accepts various deposits, including checking, savings, time, demand, and money market deposits. It also offers commercial loans, such as commercial real estate, equipment, construction, working capital, and other commercial purpose loans, as well as industrial loans; consumer loans comprising home equity and other consumer loans, as well as home equity lines of credit; residential mortgage loans; acquisition and development loans; municipal loans; and installment and other loans. In addition, the company provides renders services as trustee, executor, administrator, guardian, managing agent, custodian, and investment advisor, as well as provides other fiduciary services under the Orrstown Financial Advisors name; and offers retail brokerage services through a third-party broker/dealer arrangement. Further, it offers investment advisory, insurance, and brokerage services. The company operates through offices in Berks, Cumberland, Dauphin, Franklin, Lancaster, Perry, and York counties, Pennsylvania; and Anne Arundel, Baltimore, Howard, and Washington counties, Maryland, as well as Baltimore City, Maryland. Orrstown Financial Services, Inc. was founded in 1919 and is based in Shippensburg, Pennsylvania.
Earnings Per Share
As for profitability, Orrstown Financial Services has a trailing twelve months EPS of $3.15.
PE Ratio
Orrstown Financial Services has a trailing twelve months price to earnings ratio of 10.95. Meaning, the purchaser of the share is investing $10.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.57%.
Volume
Today’s last reported volume for Orrstown Financial Services is 123540 which is 11.61% above its average volume of 110685.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 8, 2024, the estimated forward annual dividend rate is 0.92 and the estimated forward annual dividend yield is 2.67%.
Yearly Top and Bottom Value
Orrstown Financial Services’s stock is valued at $34.49 at 11:22 EST, below its 52-week high of $35.25 and way higher than its 52-week low of $19.30.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2%, now sitting on 129.78M for the twelve trailing months.
2. Neurocrine Biosciences (NBIX)
20.8% sales growth and 15.55% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $3.32.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 44.33. Meaning, the purchaser of the share is investing $44.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.55%.
Sales Growth
Neurocrine Biosciences’s sales growth for the next quarter is 20.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 2.12B for the twelve trailing months.
Volume
Today’s last reported volume for Neurocrine Biosciences is 81956 which is 89.73% below its average volume of 798575.
3. Churchill Downs (CHDN)
15% sales growth and 43.06% return on equity
Churchill Downs Incorporated operates as a racing, online wagering, and gaming entertainment company in the United States. It operates through three segments: Live and Historical Racing, TwinSpires, and Gaming. As of December 31, 2021, the company owned and operated three pari-mutuel gaming entertainment venues with approximately 3,050 historical racing machines (HRMs) in Kentucky; TwinSpires, an online wagering platform for horse racing, sports, and iGaming; nine retail sportsbooks; and casino gaming in eight states with approximately 11,000 slot machines and video lottery terminals, and 200 table games. It also offers streaming video of live horse races, replays, and an assortment of racing and handicapping information; and provides the Bloodstock Research Information Services platform for horse racing statistical data. In addition, the company manufactures and operates pari-mutuel wagering systems for racetracks, off-track betting facilities, and other pari-mutuel wagering businesses. Churchill Downs Incorporated was founded in 1875 and is headquartered in Louisville, Kentucky.
Earnings Per Share
As for profitability, Churchill Downs has a trailing twelve months EPS of $5.45.
PE Ratio
Churchill Downs has a trailing twelve months price to earnings ratio of 24.97. Meaning, the purchaser of the share is investing $24.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.06%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.9%, now sitting on 2.62B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 21.8% and 26.7%, respectively.
4. Progress Software Corporation (PRGS)
9.8% sales growth and 17.86% return on equity
Progress Software Corporation develops, deploys, and manages business applications. The company offers OpenEdge, a development software, which builds multi-language applications for secure deployment across various platforms and devices, as well as cloud; developer tools that consists of components for user interface development for Web, mobile, desktop, chat, and AR/VR apps, as well as automated application testing and reporting tools; Sitefinity, a web content management and customer analytics platform; Corticon, a business rules management system that provides applications with decision automation and change process, and decision-related insight capabilities. It also offers DataDirect Connect, which provides data connectivity using industry-standard interfaces to connect applications running on various platforms; MOVEit that offers secure collaboration and automated file transfers of critical business information; Chef, an infrastructure automation platform to build, deploy, manage, and secure applications in multi-cloud and hybrid environments, and on-premises; and WhatsUp Gold, a network monitoring solution. In addition, the company provides Kemp LoadMaster, a load balancing solutions; and Kemp Flowmon network performance monitoring and diagnostic solutions that collect and analyze network telemetry from various sources. Further, it provides project management, implementation, custom development, programming, and other services, as well as web-enable applications; and training services. The company sells its products to end users, independent software vendors, original equipment manufacturers, and system integrators. It has operations in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company was founded in 1981 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, Progress Software Corporation has a trailing twelve months EPS of $1.63.
PE Ratio
Progress Software Corporation has a trailing twelve months price to earnings ratio of 35.52. Meaning, the purchaser of the share is investing $35.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.86%.
5. Silvercrest Asset Management Group (SAMG)
7.1% sales growth and 12.02% return on equity
Silvercrest Asset Management Group Inc., a wealth management firm, provides financial advisory and related family office services in the United States. The company serves ultra-high net worth individuals and families, as well as their trusts; endowments; foundations; and other institutional investors. It also manages funds of funds and other investment funds. The company was founded in 2002 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Silvercrest Asset Management Group has a trailing twelve months EPS of $0.94.
PE Ratio
Silvercrest Asset Management Group has a trailing twelve months price to earnings ratio of 17.69. Meaning, the purchaser of the share is investing $17.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.02%.
Sales Growth
Silvercrest Asset Management Group’s sales growth is 3.9% for the current quarter and 7.1% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 0.76 and the estimated forward annual dividend yield is 4.41%.
Yearly Top and Bottom Value
Silvercrest Asset Management Group’s stock is valued at $16.63 at 11:22 EST, way under its 52-week high of $21.72 and way higher than its 52-week low of $13.93.
